Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity.
This article is abstracted from the recently published Infectious Vaccines Partnering Terms & Agreements report.
Vaccine partnering has been quite busy since 2009, to a peak in 2010. In 2010, over 130 infectives vaccine partnering deals were being reported in a year, before falling back slightly in recent years.
The following figure illustrates the trends in infectious vaccines partnering since 2009.
Figure 1: Infectious Vaccines partnering deal frequency 2009 to 2014
Source: Current Agreements, 2014
The leading bigpharma participants in vaccine dealmaking are GSK, Sanofi and Merck and Co. Many of the other top fifty bigpharma companies appear not to play an active role in infectives vaccine research, development and commercialization.
The leading infectives therapy sector for vaccine R&D are influenza followed by viral and HIV infectives indication – see the following figure for details.
Figure 2: Vaccine partnering deals by infectives therapeutic area – 2009 to 2014
Source: Current Agreements, 2014
Deal headline value increases with stage of development, as unsurprisingly licensees are willing to pay more for more advanced infectives vaccine candidates.
The following is a summary of the top infectious vaccines partnering deals by headline value.
Figure 3: Top infectious vaccines deal making by headline value – 2009 to 2014
Source: Current Agreements, 2014
We expect to see an ongoing interest in infectious diseases partnering with the everyday development in vaccines technology.
This article is abstracted from the newly published Infectious Vaccines Partnering Terms & Agreements report.
The report provides a detailed understanding and analysis of how and why companies enter infecttious vaccines partnering deals.
The report provides full access to all infectious vaccines partnering deals announced since 2009.
The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The Infectious Vaccines Partnering Terms & Agreements report published by Current Partnering provides full details of over 500 infectious vaccines deals announced since 2009 and includes average deal terms including headline, upfront, milestone and royalty rates, where available. In addition, the report provides details of deals broken down by deal type, stage of development, company A-Z and technology type. More details here
Sources
The above information has been abstracted from the following resources:
- Infectious Vaccines Partnering Terms & Agreements report
- Current Agreements life sciences partnering, M&A and financing deals database
Shamini Thiagarajan
Related
Read: more vaccine deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: more infectives deals in pharma, biotech, life science partnering deal news, insights and glossary
Related report: Global Infectious Diseases Partnering
Related report: Vaccine Partnering Terns and Agreements
View also: Other technology type reports
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
